We are analyzing https://link.springer.com/article/10.1007/s12325-020-01555-z.

Title:
Medical Therapy for Fibroids: What Next for Ulipristal Acetate? | Advances in Therapy
Description:
Ulipristal acetate (UPA) was introduced as a novel progesterone receptor modulator as effective therapy for symptomatic fibroids. Randomised clinical trials established its effectiveness in the management of heavy menstrual bleeding due to uterine leiomyomas. The trials did not find any significant evidence of clinical harm to the participants. Recently, however, there have been reports of liver injury necessitating liver transplant in women who have had UPA treatment. This has led to the suspension of UPA as one of the medical therapies in the treatment for uterine fibroids while the European Medicines Agency (EMA) conducts a review of liver injury risk with its use. The European Medicine Agency safety committee has advised that women should stop taking 5 mg UPA and that no new patients should commence treatment with the medicine until the ongoing review is completed. In this article, we review the rise of UPA as one of the emerging medical therapies for symptomatic uterine fibroids and the subsequent reports of adverse events leading to the suspension of its use.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Insurance
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

upa, fibroids, liver, women, treatment, uterine, article, acetate, ulipristal, google, scholar, patients, medical, function, symptomatic, injury, pearl, trials, bleeding, symptoms, therapy, review, management, courses, levels, clinical, risk, safety, fibroid, normal, received, severe, progesterone, surgery, higher, study, endometrial, studies, effects, end, receptor, damage, alt, menstrual, evidence, reports, include, surgical, health, donnez,

Topics {✒️}

uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment drug-induced liver injury drug-induced liver damage hormonal therapy cytochrome enzyme inducers/inhibitors laparoscopic/robotically assisted laparoscopic �heavy menstrual bleeding heavy menstrual bleeding article download pdf long-term trial evaluating drug discov today upper limit key role abnormal bleeding patterns privacy choices/manage cookies fibroid related bleeding european medical agency 10-day double-blind treatment obstet gynaecol canada ulipristal acetate—summary european medicines agency menstrual blood loss progesterone receptor modulators reducing serum levels progesterone receptor modulator progesterone receptor modulator hepatic effects—summary unrecognised vaginal bleeding suspected drug reaction european economic area smooth muscle fibres abnormal eye sensation symptomatic uterine leiomyoma emmanuel ekanem reprod biomed online main clinical indications progesterone receptor isoforms common adverse effects effects include headaches uterine fibroid cells liver damage including pearl iv study related subjects emerging medical therapies menstrual cycle irregularity assess serum levels pearl iii extension practical clinical perspective symptoms potentially related biomed res int

Questions {❓}

Does ulipristal acetate affect surgical experience at laparoscopic myomectomy?
Liver injury and ulipristal acetate: an overstated tragedy?
Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ulipristal Acetate for Fibroids—What Next?
What Were the Main Clinical Indications for the Use of UPA and What Dose Was Recommended?
What happens after randomised controlled trials?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
         description:Ulipristal acetate (UPA) was introduced as a novel progesterone receptor modulator as effective therapy for symptomatic fibroids. Randomised clinical trials established its effectiveness in the management of heavy menstrual bleeding due to uterine leiomyomas. The trials did not find any significant evidence of clinical harm to the participants. Recently, however, there have been reports of liver injury necessitating liver transplant in women who have had UPA treatment. This has led to the suspension of UPA as one of the medical therapies in the treatment for uterine fibroids while the European Medicines Agency (EMA) conducts a review of liver injury risk with its use. The European Medicine Agency safety committee has advised that women should stop taking 5 mg UPA and that no new patients should commence treatment with the medicine until the ongoing review is completed. In this article, we review the rise of UPA as one of the emerging medical therapies for symptomatic uterine fibroids and the subsequent reports of adverse events leading to the suspension of its use.
         datePublished:2020-11-17T00:00:00Z
         dateModified:2020-11-17T00:00:00Z
         pageStart:137
         pageEnd:148
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s12325-020-01555-z
         keywords:
            Fibroids
            Medical
            Ulipristal acetate
            Women’s health
            Internal Medicine
            Oncology
            Cardiology
            Rheumatology
            Endocrinology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Advances in Therapy
            issn:
               1865-8652
               0741-238X
            volumeNumber:38
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Emmanuel Ekanem
               url:http://orcid.org/0000-0003-1477-6523
               affiliation:
                     name:University Hospitals of Leicester NHS Trust
                     address:
                        name:Speciality Trainee in Obstetrics and Gynaecology, University Hospitals of Leicester NHS Trust, Leicester, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Vikram Talaulikar
               affiliation:
                     name:University College London Hospital
                     address:
                        name:Reproductive Medicine Unit, University College London Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
      description:Ulipristal acetate (UPA) was introduced as a novel progesterone receptor modulator as effective therapy for symptomatic fibroids. Randomised clinical trials established its effectiveness in the management of heavy menstrual bleeding due to uterine leiomyomas. The trials did not find any significant evidence of clinical harm to the participants. Recently, however, there have been reports of liver injury necessitating liver transplant in women who have had UPA treatment. This has led to the suspension of UPA as one of the medical therapies in the treatment for uterine fibroids while the European Medicines Agency (EMA) conducts a review of liver injury risk with its use. The European Medicine Agency safety committee has advised that women should stop taking 5 mg UPA and that no new patients should commence treatment with the medicine until the ongoing review is completed. In this article, we review the rise of UPA as one of the emerging medical therapies for symptomatic uterine fibroids and the subsequent reports of adverse events leading to the suspension of its use.
      datePublished:2020-11-17T00:00:00Z
      dateModified:2020-11-17T00:00:00Z
      pageStart:137
      pageEnd:148
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s12325-020-01555-z
      keywords:
         Fibroids
         Medical
         Ulipristal acetate
         Women’s health
         Internal Medicine
         Oncology
         Cardiology
         Rheumatology
         Endocrinology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Advances in Therapy
         issn:
            1865-8652
            0741-238X
         volumeNumber:38
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Emmanuel Ekanem
            url:http://orcid.org/0000-0003-1477-6523
            affiliation:
                  name:University Hospitals of Leicester NHS Trust
                  address:
                     name:Speciality Trainee in Obstetrics and Gynaecology, University Hospitals of Leicester NHS Trust, Leicester, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Vikram Talaulikar
            affiliation:
                  name:University College London Hospital
                  address:
                     name:Reproductive Medicine Unit, University College London Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Advances in Therapy
      issn:
         1865-8652
         0741-238X
      volumeNumber:38
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospitals of Leicester NHS Trust
      address:
         name:Speciality Trainee in Obstetrics and Gynaecology, University Hospitals of Leicester NHS Trust, Leicester, UK
         type:PostalAddress
      name:University College London Hospital
      address:
         name:Reproductive Medicine Unit, University College London Hospital, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Emmanuel Ekanem
      url:http://orcid.org/0000-0003-1477-6523
      affiliation:
            name:University Hospitals of Leicester NHS Trust
            address:
               name:Speciality Trainee in Obstetrics and Gynaecology, University Hospitals of Leicester NHS Trust, Leicester, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Vikram Talaulikar
      affiliation:
            name:University College London Hospital
            address:
               name:Reproductive Medicine Unit, University College London Hospital, London, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Speciality Trainee in Obstetrics and Gynaecology, University Hospitals of Leicester NHS Trust, Leicester, UK
      name:Reproductive Medicine Unit, University College London Hospital, London, UK

External Links {🔗}(94)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.24s.

LINK . SPRINGER . COM {}